Sana Biotechnology Inc. came out of stealth mode semi-secretively in January 2019 with former Juno Therapeutics Inc. executives on board to develop allogeneic cell therapies. But while there were hints that it had raised substantial initial funding, Sana did not reveal until 23 June that it received the last tranche of its series A financing, bringing the total to a whopping $700m.
The Seattle-based company was assembled initially with intellectual property from Flagship Pioneering – a founding Sana investor alongside ARCH Venture Partners – and three different universities with the goal of developing off-the-shelf therapies in which donor cells would be
In addition to Flagship, ARCH and F-Prime Capital, Sana now is revealing additional investors, including the Canada Pension Plan Investment Board, Baillie Gifford, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV,
